No Result
View All Result
SUBMIT YOUR ARTICLES
  • Login
Friday, October 24, 2025
TheAdviserMagazine.com
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal
No Result
View All Result
TheAdviserMagazine.com
No Result
View All Result
Home Market Research Business

market strategy: Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay

by TheAdviserMagazine
3 months ago
in Business
Reading Time: 4 mins read
A A
market strategy: Tariff delay sparks relief rally in Indian pharma stocks: Sudip Bandyopadhyay
Share on FacebookShare on TwitterShare on LInkedIn


“The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel, we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get disentangled,” says Sudip Bandyopadhyay, Group Chairman, Inditrade Capital. What is your overall sense on the pharma pack because within that interesting developments with respect to the stock prices that yes, the largecap pharma companies are doing well, but it is the mid and the small end of the space that is picking up momentum in terms of the stock price performance and especially those beaten down names, maybe a case like Granules, Natco Pharma they have not participated much in the couple of quarters, but what a rebound. If you can help us analyse that is there anything that is changing in terms of the investor sentiment or the market is trying to look beyond two-three quarters and trying to pencil in that.Sudip Bandyopadhyay: Well, of course, what has changed significantly is the tariff announcement by President Trump. There was a sword hanging on pharma sector and at different levels different figures were being thrown around. But finally, when the announcement came, it talks about very high 200% or whatever but it is after two years. So, obviously people immediately started talking about the fact that probably it will never come because if something gets pushed back by two years obviously there is no threat of imminent tariff on pharma products, so that was a fantastic news for most Indian pharma companies because most of them or at least a lot of them have significant business in US.

They do manufacture in India and supply to US, so they would have been adversely affected by the tariff and since that is not happening, that was the point from where pharma actually we started seeing significant momentum in largecap and some midcap pharma companies. As far as overall pharma is concerned Sun Pharma does look good because some of the molecules which they were expected to commercialise a bit later in the year is getting preponed and the commercial launch is happening in US very-very soon and that kind of enthused the investors about Sun Pharma.

Overall, they have significant business in US as well as India and both the markets are expected to do good. The pricing pressure on generics is, of course, there but that has kind of reached a level where we have seen the worst.

Live Events

Of course, Glenmark did a landmark deal and it is not only for Glenmark, for the entire Indian pharmaceutical industry this was a landmark deal with R&D getting established and getting properly valued by global pharma players, so this was definitely landmark and of course, Glenmark investors were rewarded and will be rewarded further I am sure in terms of dividend or other some kind of payouts, so that is as far as Glenmark and Sun Pharma is concerned. But by and large Indian pharma can breathe a sigh of relief post the tariffs sword going away and it is back to business as usual and considering that most of the sectors are kind of still awaiting to know about the tariff and its implications, pharma is one sector where that has been taken care of. Hence, pharma is rallying, that is my view.What is your own sense when it comes to the metal pack and especially the steel because this time around not much expectation but going ahead even the industry body is looking out for a decent price hike from these levels. Help us understand that how you are analysing the impact of that on the stock prices in the times ahead.Sudip Bandyopadhyay: Well, it is definitely positive for the overall steel industry. We have to remember that globally also demand for steel is going up and naturally price hike in the domestic scenario is also expected. The uncertainty is not around demand or the price hike but the uncertainties are company specific. JSW Steel, we will definitely want to hear what is their strategy about Bhushan Steel, that is a huge problem which has been created in the recent past post the Supreme Court order and one needs to understand how that will get disentangled.

It is very critical for JSW Steel at this stage. Of course, coking coal prices of the entire industry will be interesting to understands the trend and what the management commentary is for multiple companies not only JSW Steel because that is a very-very critical ingredient as far as steel making is concerned.

By and large, we believe that the industry margins would have improved in this current quarter for which results will come out. Top line depends on company specific like JSW Steel had a scheduled maintenance, so obviously the volume will be low, but the margin improvement will be visible.



Source link

Tags: BandyopadhyaydelayIndianmarketPharmaRallyReliefsparksstocksStrategySudipTariff
ShareTweetShare
Previous Post

US Secures $15B Energy Deal With Italy

Next Post

Benefits for Indian Companies in 2025

Related Posts

edit post
Paytm and Vedanta emerge as top buys amid sectoral rotation and profit booking: CA Rudramurthy BV

Paytm and Vedanta emerge as top buys amid sectoral rotation and profit booking: CA Rudramurthy BV

by TheAdviserMagazine
October 24, 2025
0

After six consecutive sessions of solid gains, the Nifty paused for breath on Friday, slipping below the 26,000 mark. While...

edit post
Tomatoes Rs 600 per kg, capsicum Rs 300: Pakistanis are paying a heavy price after conflict with Afghanistan

Tomatoes Rs 600 per kg, capsicum Rs 300: Pakistanis are paying a heavy price after conflict with Afghanistan

by TheAdviserMagazine
October 24, 2025
0

Prices of essential goods have sharply increased in both Pakistan and Afghanistan after border closures disrupted cross-border trade between the...

edit post
Goldman aims for ‘PE returns’ with new ETF

Goldman aims for ‘PE returns’ with new ETF

by TheAdviserMagazine
October 23, 2025
0

Goldman Sachs Asset Management is teaming up with MSCI Inc. to launch an exchange-traded fund that aims to deliver returns...

edit post
Tesla’s weak earnings show how the ‘Musk Magic’ Premium is inflating its share price

Tesla’s weak earnings show how the ‘Musk Magic’ Premium is inflating its share price

by TheAdviserMagazine
October 23, 2025
0

Over the past year, on the day after Tesla unveils its latest quarterly report, this writer has calculated a metric...

edit post
Former BLS chief warns Powell is “flying blind” at a pivotal time for the Fed

Former BLS chief warns Powell is “flying blind” at a pivotal time for the Fed

by TheAdviserMagazine
October 23, 2025
0

The Federal Reserve faces an unprecedented challenge as it prepares to set interest rates next week—making its decision with almost no...

edit post
With  trillion pay package on the line, Elon Musk blasts influential firms telling shareholders to reject it: ‘Those guys are corporate terrorists’

With $1 trillion pay package on the line, Elon Musk blasts influential firms telling shareholders to reject it: ‘Those guys are corporate terrorists’

by TheAdviserMagazine
October 23, 2025
0

Elon Musk stole the show in the final minutes of Tesla’s Wednesday earnings call to label the advisory firms pushing...

Next Post
edit post
Benefits for Indian Companies in 2025

Benefits for Indian Companies in 2025

edit post
What To Do Right Away

What To Do Right Away

  • Trending
  • Comments
  • Latest
edit post
77-year-old popular furniture retailer closes store locations

77-year-old popular furniture retailer closes store locations

October 18, 2025
edit post
Pennsylvania House of Representatives Rejects Update to Child Custody Laws

Pennsylvania House of Representatives Rejects Update to Child Custody Laws

October 7, 2025
edit post
What to Do When a Loved One Dies in North Carolina

What to Do When a Loved One Dies in North Carolina

October 8, 2025
edit post
Probate vs. Non-Probate Assets: What’s the Difference?

Probate vs. Non-Probate Assets: What’s the Difference?

October 17, 2025
edit post
California Attorney Pleads Guilty For Role In 2M Ponzi Scheme

California Attorney Pleads Guilty For Role In $912M Ponzi Scheme

October 15, 2025
edit post
Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

Baby Boomers Are Flocking to This Florida Town — but Not for the Weather

October 9, 2025
edit post
2025 List Of All 177 Financial Sector Stocks From Big Sector ETFs

2025 List Of All 177 Financial Sector Stocks From Big Sector ETFs

0
edit post
The Myth of the “Robber Barons”: James Hill versus the Crony Competitors

The Myth of the “Robber Barons”: James Hill versus the Crony Competitors

0
edit post
Five airlines to resume Israel flights next week

Five airlines to resume Israel flights next week

0
edit post
If tokenized gold is just a “trust-me-bro” IOU, what’s really on-chain?

If tokenized gold is just a “trust-me-bro” IOU, what’s really on-chain?

0
edit post
7 Overlooked Pairings of VA + Medicare That Slash Out-of-Pocket Costs

7 Overlooked Pairings of VA + Medicare That Slash Out-of-Pocket Costs

0
edit post
Amazon LEGO Set Deals: LEGO Sunflowers Set only .99, plus more!

Amazon LEGO Set Deals: LEGO Sunflowers Set only $7.99, plus more!

0
edit post
The Myth of the “Robber Barons”: James Hill versus the Crony Competitors

The Myth of the “Robber Barons”: James Hill versus the Crony Competitors

October 24, 2025
edit post
If tokenized gold is just a “trust-me-bro” IOU, what’s really on-chain?

If tokenized gold is just a “trust-me-bro” IOU, what’s really on-chain?

October 24, 2025
edit post
Paytm and Vedanta emerge as top buys amid sectoral rotation and profit booking: CA Rudramurthy BV

Paytm and Vedanta emerge as top buys amid sectoral rotation and profit booking: CA Rudramurthy BV

October 24, 2025
edit post
Comprehensive Sodium-Ion Battery Market Analysis: Demand Forecast

Comprehensive Sodium-Ion Battery Market Analysis: Demand Forecast

October 24, 2025
edit post
Alnylam Pharmaceuticals – ALNY: Volkskrankheit Bluthochdruck im Visier!

Alnylam Pharmaceuticals – ALNY: Volkskrankheit Bluthochdruck im Visier!

October 24, 2025
edit post
China strikes conciliatory tone ahead of expected Trump-Xi meeting

China strikes conciliatory tone ahead of expected Trump-Xi meeting

October 24, 2025
The Adviser Magazine

The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.

CATEGORIES

  • 401k Plans
  • Business
  • College
  • Cryptocurrency
  • Economy
  • Estate Plans
  • Financial Planning
  • Investing
  • IRS & Taxes
  • Legal
  • Market Analysis
  • Markets
  • Medicare
  • Money
  • Personal Finance
  • Social Security
  • Startups
  • Stock Market
  • Trading

LATEST UPDATES

  • The Myth of the “Robber Barons”: James Hill versus the Crony Competitors
  • If tokenized gold is just a “trust-me-bro” IOU, what’s really on-chain?
  • Paytm and Vedanta emerge as top buys amid sectoral rotation and profit booking: CA Rudramurthy BV
  • Our Great Privacy Policy
  • Terms of Use, Legal Notices & Disclosures
  • Contact us
  • About Us

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • Financial Planning
    • Financial Planning
    • Personal Finance
  • Market Research
    • Business
    • Investing
    • Money
    • Economy
    • Markets
    • Stocks
    • Trading
  • 401k Plans
  • College
  • IRS & Taxes
  • Estate Plans
  • Social Security
  • Medicare
  • Legal

© Copyright 2024 All Rights Reserved
See articles for original source and related links to external sites.